Search results
Amgen 'encouraged' by weight-loss drug interim data, shares jump
Reuters· 6 days ago, opens new tab on Thursday said it was very encouraged after completing an interim analysis of its...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 7 days agoNew York, USA, May 02, 2024 (GLOBE NEWSWIRE) -- Inflammatory Bowel Disease Market To Exhibit Significant Growth by 2032, Predicts DelveInsight | Key Companies Developing Therapies - Arena Pharmaceuticals, Pfizer, Abivax, Janssen, Celgene, Eli
Caring for older Americans’ teeth and gums is essential but Medicare generally doesn’t cover it
Ohio Capital Journal via Yahoo News· 7 days agoBy Frank Scannapieco, University at Buffalo and Ira Lamster, Stony Brook University (The State...
Amgen 'encouraged' by weight-loss drug interim data, shares jump By Reuters
Investing.com· 6 days agoInvestors are focused on Amgen's pipeline of experimental weight-loss drugs, and the company said it...
722 Shares in Amgen Inc. (NASDAQ:AMGN) Purchased by McAdam LLC
ETF DAILY NEWS· 7 days agoMcAdam LLC purchased a new position in Amgen Inc. (NASDAQ:AMGN – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission ...
Tiziana Life Sciences (LON:TILS) Shares Cross Below 200 Day Moving Average of $58.50
ETF DAILY NEWS· 5 days agoTiziana Life Sciences PLC (LON:TILS – Get Free Report)’s share price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 58.50 ($0.73 ...
New Advanced Infusion Center location looks to 'help the community'
Appeal-Democrat, Marysville, Calif. via Yahoo News· 6 days agoMay 2—Advanced Infusion Center celebrated the grand opening of its new location in Yuba City last week. The center is a physician-owned outpatient center that offers the administration of different ...
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Rating of “Moderate Buy” from Analysts
ETF DAILY NEWS· 5 days agoIGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) has earned an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, MarketBeat.com ...